RICE Trial: Rifaximin In Chronic Hepatic Encephalopathy - A Randomized, Controlled Trial
Sponsor: Bausch Health Americas, Inc.
Terminated
Difficult to recruit participants
Other terminated trials from Bausch Health Americas, Inc.
- AKN · Phase PHASE3 · Apr 2024
- Irritable Bowel Syndrome · Phase PHASE2 · Nov 2021
- Severe Hepatic Impairment · Phase PHASE4 · Feb 2020
- Crohn's Disease · Phase PHASE3 · Oct 2017
- Crohn's Disease · Phase PHASE3 · Aug 2017
More terminations from Bausch Health Americas, Inc.
Other Hepatic Encephalopathy trials with similar outcome
This PHASE3 trial investigates Hepatic Encephalopathy and is currently terminated or withdrawn. Bausch Health Americas, Inc. leads this study, which shows 8 recorded versions since 2006 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
Dec 2021 — Jul 2024 [monthly]
Terminated PHASE3
-
Jan 2021 — Dec 2021 [monthly]
Terminated PHASE3
-
Oct 2019 — Jan 2021 [monthly]
Terminated PHASE3
Status: Unknown Status → Terminated
▶ Show 3 earlier versions
-
Jun 2019 — Oct 2019 [monthly]
Unknown Status PHASE3
-
Jun 2018 — Jun 2019 [monthly]
Unknown Status PHASE3
-
Jan 2017 — Jun 2018 [monthly]
Unknown Status PHASE3
First recorded
Aug 2006
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Bausch Health Americas, Inc.
- University of Miami
For direct contact, visit the study record on ClinicalTrials.gov .